Evaluation of triple negative breast cancer with heterogeneous immune infiltration

被引:3
|
作者
Quintana, Angela [1 ]
Arenas, Enrique Javier [2 ,3 ]
Bernado, Cristina [2 ]
Navarro, Jose Fernandez [4 ]
Gonzalez, Jonatan [4 ]
Esteve-Codina, Anna [5 ,6 ]
Moline, Teresa [7 ]
Marti, Merce [8 ]
Curigliano, Giuseppe [9 ,10 ]
Schmid, Peter [11 ]
Peg, Vicente [3 ,7 ,12 ]
Arribas, Joaquin [2 ,3 ,13 ,14 ,15 ]
Cortes, Javier [1 ,16 ,17 ,18 ]
机构
[1] Vall dHebron Inst Oncol, Breast Canc Unit, Barcelona, Spain
[2] Vall dHebron Inst Oncol, Preclin Res Program, Barcelona, Spain
[3] Biomed Res Network Ctr Oncol CIBERONC, Madrid, Spain
[4] Vall dHebron Inst Oncol, Bioinformat Dept, Barcelona, Spain
[5] Barcelona Inst Sci & Technol BIST, Ctr Genom Regulat, CNAG CRG, Barcelona, Spain
[6] Univ Pompeu Fabra UPF, Barcelona, Spain
[7] Vall dHebron Univ Hosp, Dept Pathol, Barcelona, Spain
[8] Univ Autonoma Barcelona, Dept Biol Cellular Fisiol & Immunol, Barcelona, Spain
[9] European Inst Oncol, IRCCS, Milan, Italy
[10] Univ Milan, Dept Oncol & Hemato Oncol, Milan, Italy
[11] Queen Mary Univ London, Barts Canc Inst, London, England
[12] Univ Autonoma Barcelona, Dept Med, Barcelona, Spain
[13] Univ Pompeu Fabra, Dept Med & Ciencies Vida, Barcelona, Spain
[14] Catalan Inst Res & Adv Studies ICREA, Barcelona, Spain
[15] Inst Hosp Mar Invest Med IMIM, Canc Res Program, Barcelona, Spain
[16] Univ Europea Madrid, Fac Biomed & Hlth Sci, Dept Med, Madrid, Spain
[17] Int Breast Canc Ctr, Quironsalud Grp, Pangaea Oncol, Barcelona, Spain
[18] Med Scientia Innovat Res MedSIR, Barcelona, Spain
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
tumor-infiltrating lymphocytes; intratumor heterogeneity; triple negative breast cancer; transcriptomics; immune cell abundance; PEMBROLIZUMAB PLUS CHEMOTHERAPY; PROGNOSTIC VALUE; OPEN-LABEL; LYMPHOCYTES;
D O I
10.3389/fimmu.2023.1149747
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IntroductionTumor infiltrating lymphocytes (TILs) are known to be a prognostic and predictive biomarker in breast cancer, particularly in triple negative breast cancer (TNBC) patients. International guidelines have been proposed to evaluate them in the clinical setting as a continuous variable, without a clear defined cut-off. However, there are scenarios where the immune infiltration is heterogeneous that some areas of the patient's tumour have high numbers of TILs while other areas completely lack them. This spontaneous presentation of a heterogeneous immune infiltration could be a great opportunity to study why some tumours present TILs at diagnosis but others do not, while eliminating inter patient's differences. MethodsIn this study, we have identified five TNBC patients that showed great TIL heterogeneity, with areas of low (<= 5%) and high (>= 50%) numbers of TILs in their surgical specimens. To evaluate immune infiltration heterogeneity, we performed and analyzed bulk RNA-sequencing in three independent triplicates from the high and low TIL areas of each patient. ResultsGene expression was homogeneous within the triplicates in each area but was remarkable different between TILs regions. These differences were not only due to the presence of TILs as there were other non-inflammatory genes and pathways differentially expressed between the two areas. DiscussionThis highlights the importance of intratumour heterogeneity driving the immune infiltration, and not patient's characteristics like the HLA phenotype, germline DNA or immune repertoire.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Stromal tumour lymphocyte infiltration as a prognostic tool in triple negative breast cancer
    Shalaby, A.
    Walsh, E.
    Glynn, S.
    Callagy, G.
    VIRCHOWS ARCHIV, 2017, 471 : S57 - S57
  • [22] Clinical Imaging of the Heterogeneous Group of Triple-negative Breast Cancer
    Mueller, Martin
    Gueth, Uwe
    Varga, Zsuzsanna
    Reeve, Kelly
    Bjelic-Radisic, Vesna
    Fleisch, Markus
    Tausch, Christoph J.
    Elfgen, Constanze
    ANTICANCER RESEARCH, 2020, 40 (04) : 2125 - 2131
  • [23] Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer
    Boissiere-Michot, Florence
    Chabab, Ghita
    Mollevi, Caroline
    Guiu, Severine
    Lopez-Crapez, Evelyne
    Ramos, Jeanne
    Bonnefoy, Nathalie
    Lafont, Virginie
    Jacot, William
    CANCERS, 2021, 13 (04) : 1 - 20
  • [24] Identification of Molecular Profiles of Triple-Negative Breast Cancer in Colombian Patients and Their Association with Immune Infiltration and Disease Prognosis
    Huertas Caro, C. A.
    Lopez-Kleine, L.
    Ballen, D. F.
    Mejia, J. C.
    Sua-Villegas, L. F.
    Cock-Rada, A.
    Zabaleta, J.
    Serrano-Gomez, S. J.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S160 - S160
  • [25] BTN3A2 serves as a prognostic marker and favors immune infiltration in triple-negative breast cancer
    Cai, Peian
    Lu, Zhenhui
    Wu, Jianjun
    Qin, Xiong
    Wang, Zetao
    Zhang, Zhi
    Zheng, Li
    Zhao, Jinmin
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2020, 121 (03) : 2643 - 2654
  • [26] Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer
    Bobrie, Angelique
    Massol, Oceane
    Ramos, Jeanne
    Mollevi, Caroline
    Lopez-Crapez, Evelyne
    Bonnefoy, Nathalie
    Boissiere-Michot, Florence
    Jacot, William
    CANCERS, 2022, 14 (19)
  • [27] MerTK tumorigenesis and immune evasion mechanisms in triple negative breast cancer
    Iida, Mari
    Kostecki, Kourtney
    Kranjac, Carlene A.
    Glitchev, Christine
    Yang, David T.
    Wheeler, Deric L.
    CANCER RESEARCH, 2022, 82 (12)
  • [28] BRCAness Phenotype and Immune Microenvironment in Triple-Negative Breast Cancer
    Ramos Navas, Luisa Ayelen
    Esquivel Vazquez, Beatriz
    Salido Ruiz, Eduardo
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 932 - 933
  • [29] Immune-related biomarkers in triple-negative breast cancer
    Zhang, Juan
    Tian, Qi
    Zhang, Mi
    Wang, Hui
    Wu, Lei
    Yang, Jin
    BREAST CANCER, 2021, 28 (04) : 792 - 805
  • [30] Novel immune targets for the treatment of triple-negative breast cancer
    Corti, Chiara
    Nicolo, Eleonora
    Curigliano, Giuseppe
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2021, 25 (10) : 815 - 834